Cargando…

Biomarkers for Homologous Recombination Deficiency in Cancer

DNA double-strand breaks foster tumorigenesis and cell death. Two distinct mechanisms can be activated by the cell for DNA repair: the accurate mechanism of homologous recombination repair or the error-prone non-homologous end joining. Homologous Recombination Deficiency (HRD) is associated with sen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wagener-Ryczek, Svenja, Merkelbach-Bruse, Sabine, Siemanowski, Janna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8304859/ https://www.ncbi.nlm.nih.gov/pubmed/34203281 http://dx.doi.org/10.3390/jpm11070612

Ejemplares similares

Comparison of in situ and extraction-based methods for the detection of MET amplifications in solid tumors
por: Heydt, Carina, et al.
Publicado: (2019)

Molecular Characteristics of Radon Associated Lung Cancer Highlights MET Alterations
por: Gamerith, Gabriele, et al.
Publicado: (2022)

Detection of gene fusions using targeted next-generation sequencing: a comparative evaluation
por: Heydt, Carina, et al.
Publicado: (2021)

Managing Difficulties of Microsatellite Instability Testing in Endometrial Cancer-Limitations and Advantages of Four Different PCR-Based Approaches
por: Siemanowski, Janna, et al.
Publicado: (2021)

Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors
por: Wagener-Ryczek, Svenja, et al.
Publicado: (2020)

Overview of Molecular Detection Technologies for MET in Lung Cancer
por: Heydt, Carina, et al.
Publicado: (2023)

Immune profile and immunosurveillance in treatment-naive and neoadjuvantly treated esophageal adenocarcinoma
por: Wagener-Ryczek, Svenja, et al.
Publicado: (2020)

Determinants of Homologous Recombination Deficiency in Pancreatic Cancer
por: Wattenberg, Max M., et al.
Publicado: (2021)

Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types
por: Takamatsu, Shiro, et al.
Publicado: (2021)

Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types
por: Takamatsu, Shiro, et al.
Publicado: (2022)

Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers
por: Watkins, Johnathan A, et al.
Publicado: (2014)

Homologous Recombination Deficiencies and Hereditary Tumors
por: Yamamoto, Hideki, et al.
Publicado: (2021)

Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP Inhibitors
por: Miller, Rowan E, et al.
Publicado: (2022)

Proficiency testing of PIK3CA mutations in HR+/HER2-breast cancer on liquid biopsy and tissue
por: Vollbrecht, Claudia, et al.
Publicado: (2022)

Homologous Recombination Deficiency (HRD) in Cutaneous Oncology
por: Akinjiyan, Favour A., et al.
Publicado: (2023)

Pan-cancer landscape of homologous recombination deficiency
por: Nguyen, Luan, et al.
Publicado: (2020)

Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity
por: van Wilpe, Sandra, et al.
Publicado: (2021)

PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers
por: Keung, Man Yee T., et al.
Publicado: (2019)

Exploiting the Prevalence of Homologous Recombination Deficiencies in High-Grade Serous Ovarian Cancer
por: Bouberhan, Sara, et al.
Publicado: (2020)

Clinical use and mechanisms of resistance for PARP inhibitors in homologous recombination-deficient cancers
por: Janysek, Dawn C., et al.
Publicado: (2021)

Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management
por: da Cunha Colombo Bonadio, Renata Rodrigues, et al.
Publicado: (2018)

The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair
por: Pacheco-Barcia, Vilma, et al.
Publicado: (2022)

Homologous Recombination Deficiency in Ovarian Cancer: from the Biological Rationale to Current Diagnostic Approaches
por: Mangogna, Alessandro, et al.
Publicado: (2023)

Homologous Recombination Deficiency Scar: Mutations and Beyond—Implications for Precision Oncology
por: van der Wiel, Alexander M. A., et al.
Publicado: (2022)

Homologous Recombination Deficiency: Concepts, Definitions, and Assays
por: Stewart, Mark D, et al.
Publicado: (2022)

Targeting homologous recombination deficiency in uterine leiomyosarcoma
por: Dall, Genevieve, et al.
Publicado: (2023)

Leveraging homologous recombination repair deficiency in sarcoma
por: Slade, Dea, et al.
Publicado: (2023)

Genomic Determinants of Homologous Recombination Deficiency across Human Cancers
por: Qing, Tao, et al.
Publicado: (2021)

Mismatch Repair Deficiency and Somatic Mutations in Human Sinonasal Tumors
por: Hieggelke, Lena, et al.
Publicado: (2021)

Multi-scale characterisation of homologous recombination deficiency in breast cancer
por: Jacobson, Daniel H., et al.
Publicado: (2023)

Normalized LST Is an Efficient Biomarker for Homologous Recombination Deficiency and Olaparib Response in Ovarian Carcinoma
por: Christinat, Yann, et al.
Publicado: (2023)

Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis
por: Casolino, Raffaella, et al.
Publicado: (2021)

Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review
por: Pellegrino, B., et al.
Publicado: (2020)

Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature
por: Frey, Melissa K., et al.
Publicado: (2017)

Homologous Recombination Deficiency Testing for BRCA-Like Tumors: The Road to Clinical Validation
por: Ladan, Marjolijn M., et al.
Publicado: (2021)

Teenage-Onset Colorectal Cancers in a Digenic Cancer Predisposition Syndrome Provide Clues for the Interaction between Mismatch Repair and Polymerase δ Proofreading Deficiency in Tumorigenesis
por: Schamschula, Esther, et al.
Publicado: (2022)

Impact of homologous recombination deficiency biomarkers on outcomes in patients with early breast cancer: a systematic review protocol
por: Liao, Hao, et al.
Publicado: (2022)

Biomarker Assessment of Homologous Recombination Deficiency in Epithelial Ovarian Cancer: Association With Progression-Free Survival After Surgery
por: Yi, Huan, et al.
Publicado: (2022)

Identification of biomarkers complementary to homologous recombination deficiency for improving the clinical outcome of ovarian serous cystadenocarcinoma
por: Shi, Zhiwen, et al.
Publicado: (2021)

Identification of immunotherapy biomarkers for improving the clinical outcome of homologous recombination deficiency patients with lung adenocarcinoma
por: Zhou, Xiang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9jgbhggiklfhd8dlh3i3il1ebu